Department of Gynecology, The First Hospital of Jilin University, No.71 Xinmin Avenue, Chaoyang District, Jilin, 130021, Changchun, China.
Department of Hematology, The First Hospital of Jilin University, No.71 Xinmin Avenue, Chaoyang District, Jilin, 130021, Changchun, China.
J Ovarian Res. 2023 Aug 16;16(1):166. doi: 10.1186/s13048-023-01245-8.
To comprehensively evaluate the influence of dienogest (DNG) versus non-DNG pretreatment on in vitro fertilization and embryo transfer (IVF-ET) outcomes for patients with endometriosis.
PubMed, Embase, Cochrane Library, Web of Science, CNKI, WanFang, and VIP were comprehensively searched for relevant publications until September 14, 2022. Primary outcomes included clinical pregnancy rate and live birth rate. Secondary outcomes included retrieved oocytes, mature oocytes, blastocysts, growing follicles, transferrable embryos, fertilization rate, implantation rate, and miscarriage rate. Subgroup analysis was performed according to different grouping methods and embryo types.
Five studies of 568 females with endometriosis were involved in this systematic review and meta-analysis. DNG treatment exhibited similar effects to non-DNG treatment on either the primary or the secondary outcomes (all P > 0.05). The DNG group had a significantly greater clinical pregnancy rate than the non-hormonal treatment group (pooled relative risk [RR]: 2.055, 95% confidence interval [CI]: 1.275, 3.312, P = 0.003), and exhibited a significantly lower clinical pregnancy rate than the long gonadotropin-releasing hormone agonist (GnRH-a) group (RR: 0.542, 95%CI: 0.321, 0.916, P = 0.022). For patients undergoing fresh embryo transfer, the DNG group displayed a significantly greater clinical pregnancy rate versus the non-DNG group (pooled RR: 1.848, 95%CI: 1.234, 2.767, P = 0.003). Patients receiving DNG had a significantly greater live birth rate than those with non-hormonal treatment (pooled RR: 2.136, 95%CI: 1.223, 3.734, P = 0.008), while having a significantly lower live birth rate than the long GnRH-a group (RR: 0.441, 95%CI: 0.214, 0.907, P = 0.026). While using fresh embryos, patients with DNG treatment had an increased live birth rate, compared with those without DNG treatment (pooled RR: 2.132, 95%CI: 1.090, 4.169, P = 0.027).
DNG treatment may have similar effects to non-DNG treatment on IVF-ET outcomes. The clinical pregnancy rate and live birth rate after DNG treatment may be significantly higher than those after non-hormonal treatment. More evidence is warranted to corroborate these findings.
全面评估地诺孕素(DNG)与非 DNG 预处理对子宫内膜异位症患者体外受精-胚胎移植(IVF-ET)结局的影响。
系统检索 PubMed、Embase、Cochrane 图书馆、Web of Science、中国知网(CNKI)、万方、维普等数据库,检索时限均为建库至 2022 年 9 月 14 日,收集关于 DNG 与非 DNG 预处理对子宫内膜异位症患者 IVF-ET 结局影响的研究。主要结局指标为临床妊娠率和活产率。次要结局指标包括获卵数、成熟卵数、囊胚数、生长卵泡数、可移植胚胎数、受精率、种植率和流产率。根据不同的分组方法和胚胎类型进行亚组分析。
本系统评价和荟萃分析共纳入 5 项研究 568 例子宫内膜异位症患者。DNG 治疗与非 DNG 治疗在主要结局或次要结局方面的效果相似(均 P>0.05)。DNG 组的临床妊娠率显著高于非激素治疗组(合并相对危险度[RR]:2.055,95%置信区间[CI]:1.2753.312,P=0.003),显著低于长 GnRH-a 组(RR:0.542,95%CI:0.3210.916,P=0.022)。对于行新鲜胚胎移植的患者,DNG 组的临床妊娠率显著高于非 DNG 组(合并 RR:1.848,95%CI:1.2342.767,P=0.003)。DNG 组的活产率显著高于非激素治疗组(合并 RR:2.136,95%CI:1.2233.734,P=0.008),显著低于长 GnRH-a 组(RR:0.441,95%CI:0.2140.907,P=0.026)。对于使用新鲜胚胎的患者,DNG 治疗组的活产率高于非 DNG 治疗组(合并 RR:2.132,95%CI:1.0904.169,P=0.027)。
DNG 治疗与非 DNG 治疗对 IVF-ET 结局的影响可能相似。DNG 治疗后的临床妊娠率和活产率可能显著高于非激素治疗后。需要更多的证据来证实这些发现。